Introduction

Alanine aminotransferase (ALT) is an enzyme found predominantly in the liver but also in other tissues such as the kidneys, heart, and muscle cells. An increase in ALT serum levels indicates definite liver cell injury due to many causes. An ALT blood test is often included in a liver panel and comprehensive metabolic panel to assess for damage to the liver. 

The liver has a central and critical biochemical role in the metabolism, digestion, detoxification, and elimination of substances from the body.[1] All blood from the intestinal tract initially passes through the liver, where products derived from the digestion of food are processed, transformed, and stored.[2] These include amino acids, carbohydrates, fatty acids, cholesterol, lipids, vitamins, and minerals.

Most major plasma proteins (except immunoglobulins and the von Willebrand factor) are mainly or exclusively synthesized in the liver. The liver responds to multiple hormonal and neural stimuli to regulate blood glucose concentrations.[3] Not only does the organ extract glucose from the blood to generate energy, but it also stores dietary glucose as glycogen for later use. The liver is also the major site for gluconeogenesis, which is critical for maintaining blood glucose concentration in the fasting state.[4] The liver is central in lipid metabolism; it extracts and processes dietary lipids and is the principal site of cholesterol, triglyceride, and lipoprotein synthesis.[5] Another major liver function is the synthesis of bile acids from cholesterol, with the secretion of these compounds into the bile, which facilitates the absorption of dietary fat and fat-soluble vitamins.[6]

The liver is also the primary site of metabolism of both endogenous substances and exogenous compounds (eg, drugs and toxins). This process, known as biotransformation, converts lipophilic substances to hydrophilic ones for subsequent elimination.[5] The liver is a major site of hormone catabolism and regulates plasma hormone concentrations.[6] The liver is also involved in hormone synthesis, producing the hormones insulin-like growth factor 1 (IGF-1), angiotensinogen, hepcidin, thrombopoietin, erythropoietin, and the prohormone 25-OH vitamin D. Many of these hepatic functions can be assessed by laboratory procedures to gain insight into the integrity of the liver.[1]

As a large organ, the liver has extensive reserve capacity to perform its functions in coordination with other organs. Individuals with liver disease maintain normal function despite extensive liver damage. In such cases, liver disease may be recognized only using tests that detect injury.[2] Most commonly, this is accomplished by measuring the plasma activities of enzymes found within liver cells, which are released in specific patterns with different forms of injury.[7] Chronic liver injury involves fibrosis in the liver. Markers of the fibrotic process might indicate the degree of injury.[8] Chronic damage is often due to chronic inflammation. Cytokines can alter the liver's protein production pattern, making it possible to detect inflammation, not necessarily related to the liver.[9] Some proteins are produced in increased amounts with liver regeneration and neoplasia; the markers may be useful in detecting liver cell proliferation.[10]

This review focuses on the significance of ALT in assessing hepatic injury and malfunction. ALT is aggregated primarily in the cytosol of hepatocytes, consists of 496 amino acids, and has a half-life of approximately 47 hours.[11] ALT is detectable in serum at low concentrations (typically <30 IU/L). However, any process that leads to loss of hepatocyte membrane integrity or necrosis results in the release of ALT in high concentrations in the plasma.[2]

Therefore, the elevation of serum ALT concentration is sensitive but not specific to measure hepatocellular injury, as the degree of elevation cannot determine the exact cause.[1] The most common causes are alcohol-induced liver injury, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), chronic hepatitis B or C, autoimmune hepatitis, and drug or herbal supplement-induced liver injury.[4] Other causes include hemochromatosis, vascular disease, acute viral hepatitis, and genetic disorders affecting the liver.[7]

Etiology and Epidemiology

The liver transaminases, mainly ALT and aspartate aminotransferase (AST), are aggregated in the cytosol of hepatocytes. These enzymes are normally detectable in the serum at low concentrations, typically <30 IU/L.[12][13] However, any process that leads to loss of hepatocyte membrane integrity or necrosis releases these enzymes into the blood, where the elevated concentrations can be measured.[14] Transaminase elevation is frequent in primary care medicine, affecting 10% to 30% of the U.S. population. Less than 5% of patients with elevated transaminases will have severe liver conditions.[15] 

ALT increases affect 8.9% of the U.S. population.[16] Several physiological and risk factors may contribute to the serum levels of these enzymes, including age, sex, body mass index, pubertal age, elevated levels of triglycerides, insulin resistance, and blood glucose level.[17][18]

Physiological Factors

1. Extreme physical exertion can induce a reversible elevation in serum ALT, approximately 2 to 2.2-fold higher than the normal limit.[19] While the source of elevated ALT in these individuals could be non-hepatic, it is likely released from the exercising skeletal muscles.
2. ALT activity has a diurnal variation; the nadir value is at 4:00 hr, and the peak value is at 16:00 hr.[20]
3. ALT is higher in males compared to females. These gender-based differences in ALT levels are possibly related to hormonal differences between males and females.[21]
4. Ethnicity affects ALT levels. Research shows that Mexican Americans have a higher ALT elevation prevalence than other ethnicities.[22] This finding could be related to higher incidences of metabolic syndrome, a major cause of elevated ALT in Mexican Americans.
5. Research has found no association between the hypoxia-inducible factor 3 alpha subunit (HIF3A) rs3826795 polymorphism and ALT. However, a significant interaction between obesity and rs3826795 concerning ALT was found. Rs382695 G-allele number elevation of ALT is significant only in obese children but not non-obese children.[23]
6. In another study, Bekkelund and Jorde found that serum ALT was associated with body fat mass index in men. ALT was associated with lean mass index in men and women in the overweight and obese population.[24] They found body mass index to be the most determining factor for ALT, and gender was the most influencing factor for AST.[25]

Pathological Causes

1. Depending on the region, alcoholic hepatitis and non-alcoholic fatty liver disease (NAFLD) are considered the most common causes of abnormally high ALT levels.
2. Non-alcoholic steatohepatitis (NASH)
3. Chronic hepatitis B or C
4. Autoimmune hepatitis
5. Alpha-1 antitrypsin deficiency
6. Drug-associated, occupational exposure, or herbal supplement-induced liver injury
7. Hemochromatosis
8. Wilson disease
9. Celiac disease
10. Ischemic hepatitis
11. Budd-Chiari syndrome
12. Vascular disease
13. Genetically-related conditions affecting the liver[26]

Pathophysiology

ALT catalyzes the transfer of amino groups from the L-alanine to alpha-ketoglutarate, and the conversion products are L-glutamate and pyruvate. The process is critical in the liver in the tricarboxylic acid (TCA) cycle. Pyruvate can be used in the citric acid cycle to produce cellular energy. The coenzyme needed for this reaction is pyridoxal 5'-phosphate, also known as vitamin B6.[27] The pyridoxal 5'-phosphate (P-5′-P) is bound to the inactive apoenzyme and is a true prosthetic group. The pyridoxal 5'-phosphate attached to the apoenzyme accepts the amino group from the first substrate, aspartate or alanine, to form enzyme-bound pyridoxamine-5′-phosphate and the first reaction product, oxaloacetate or pyruvate, respectively.[28] The coenzyme in the amino form then transfers its amino group to the second substrate, 2-oxoglutarate, to form the second product, glutamate. The pyridoxal 5'-phosphate (P-5′-P) is regenerated.[29]

Both coenzyme-deficient apoenzymes and holoenzymes may be present in serum.[30] Therefore, adding P-5′-P under measurement conditions that facilitate recombination with the enzymes usually increases aminotransferase activity. For clinical assays, following the principle that all factors affecting the reaction rate must be optimized and controlled, adding P-5′-P in aminotransferase methods is recommended to ensure that all enzymatic activity is measured.[31]

ALT is found ubiquitously throughout the human body, in the kidney, myocardium, skeletal muscle, brain, pancreas, spleen, and lungs. More specifically, the highest tissue concentration of ALT activity is in the cytosol of hepatocytes. The activity of ALT in hepatocytes is approximately 3000 times higher than that of serum ALT activity.[32] Therefore, in patients with acute or chronic hepatocellular injury, the release of ALT from dying or damaged hepatocytes increases serum ALT levels. The half-life of ALT is approximately 47 hours in circulation.[33]

Specimen Requirements and Procedure

According to the International Standard ISO 6710, the light green cap contains lithium-heparin and is used for the hepatic function panel.[34] A trained clinician will disinfect the skin and wrap an elastic strap around the arm to visualize a vein. A blood sample is collected. The sample must be placed in the correctly colored cap, as the various color caps have a particular additive.[35] After the specimen is collected and fulfills the requirements, it is sent for testing. Hepatic function panels evaluate for ALT through blood samples. The quality of blood specimens is vital to decrease laboratory errors, prevent diagnosis delay, and ensure a proper diagnosis.[36] All specimens should undergo measurement of the hemolysis index, as hemolyzed blood is considered unsuitable for testing. The inappropriate quality or sample volume contributes to approximately 80% to 90% of laboratory errors.[37]

A hemolysis index assesses the sample at specific wavelengths to determine the potential concentration of cell-free hemoglobin and ensure quality. If the hemolysis index is unavailable, a visual inspection should be conducted.[38] Blood specimens with fibrin strands or clots should not be used for testing. Blood tubes filled at less than 90% of their nominal volume should not be used for testing to maintain specimen integrity.[39] Only in emergent situations that require evaluating prothrombin time and fibrinogen assay are blood coagulation tubes filled to 70% of their nominal volume usable.[40]

Diagnostic Tests

A panel of laboratory tests to assess liver functions, also known as the liver function test, is commonly used in clinical practice. The liver function test comprises the following:[40]

1. Serum bilirubin
2. Serum alanine aminotransferase (ALT)
3. Serum aspartate transaminase (AST)
4. Serum alkaline phosphatase (ALP)
5. Serum gamma-glutamyltransferase (GGT)
6. Prothrombin time or an International Normalized ratio (INR)
7. Serum albumin

Testing Procedures

The liver function tests are performed on semi-automatic or fully automated analyzers, which are based on the principle of photometry. Photometry is the measurement of light absorbed in the ultraviolet (UV) to visible (VIS) to infrared (IR) range. This measurement determines the amount of an analyte in a solution or liquid. Photometers utilize a specific light source and detectors that convert light through a sample solution into a proportional electrical signal. These detectors may be photodiodes, photoresistors, or photomultipliers.[41] Photometry uses Beer–Lambert’s law to calculate coefficients obtained from the transmittance measurement. A test-specific calibration function establishes a correlation between absorbance and analyte concentration to achieve highly accurate measurements.[42]

Interfering Factors

Patients are instructed to avoid certain medications and foods before a hepatic function panel to ensure the integrity of blood specimens.[43] Drug hepatotoxicity can be non-idiosyncratic or idiosyncratic. Also, drug-associated hepatotoxicity can be classified as immune-mediated and non-immune-mediated. The incidence of drug-induced liver injury is 19 cases per 100,000 persons. The most common drug causing drug-induced liver injury is amoxicillin or clavulanate.[44][45] Hepatitis E infection can masquerade drug-induced liver injury in 3% to 13% of the cases.[46] Tacrine, a medication for Alzheimer disease, was withdrawn from the market because of significant liver injury. This medication caused elevations of ALT levels that trended as high as 20 times the normal reference level.[47] 

Up to 5% of patients on statin medications developed elevations in ALT.[48] Ceftriaxone, phenytoin, carbamazepine, cotrimoxazole, and allopurinol have been reported to cause liver injury. Also, tricyclic antidepressants, imipramine, and amitriptyline have links to elevations in ALT.[49] Elevation of serum ALT and AST has been reported in patients taking these medications: isoniazid, pyrazinamide, rifampicin, ibuprofen, or dapsone.[50] The website maintained by the National Institute of Diabetes and Digestive Diseases (NIDDK) is a valuable resource for clinicians and researchers interested in liver hepatotoxicity and other drugs that can increase serum ALT. As stated earlier, periods of intense exercise should be avoided before testing, as this may increase ALT levels.[51]

Results, Reporting, and Critical Findings

The results of a hepatitis panel should correlate with the initial findings in a complete history and physical examination. A thorough review should include essential questions regarding the patient’s age, past medical history (diabetes, obesity, hyperlipidemia, inflammatory bowel disease, celiac sprue, thyroid disorders, autoimmune hepatitis, acquired muscle disorders, alcohol consumption, medication use, toxin exposure), and family history of genetic liver conditions (Wilson disease, alpha-1-antitrypsin deficiency, hereditary hemochromatosis).[32]

A review of systems should also include signs and symptoms of chronic liver disease such as jaundice, ascites, peripheral edema, hepatosplenomegaly, gynecomastia, testicular hypotrophy, muscle wasting, encephalopathy, pruritus, and gastrointestinal bleeding.[52] Other tests that help determine the cause of elevated transaminase levels found on a hepatitis panel include fasting lipid levels, hemoglobin A1c level, fasting glucose, complete blood count with platelets, a complete metabolic panel, iron studies, hepatitis C antibody, and hepatitis B surface antigen testing.[53] A hepatitis panel reference range can fluctuate amongst different laboratories. Reported values also vary depending on gender, body mass index, and past medical history. Repeated liver enzymes are typically unnecessary in the workup for elevated transaminase levels.[54]

Clinical Significance

An increase in ALT serum levels indicates definite liver cell injury due to many causes.[55] Although specific hepatic diseases are associated with an elevation in ALT levels, no correlation exists between the absolute peak of the ALT elevation and the magnitude of hepatic injury.[54] An increase in both AST and ALT serum levels is common. ALT levels greater than 1000 U/L should be considered acute ischemic liver injury, severe drug-induced liver injury, or acute viral hepatitis. Other causes include common bile duct stones and hepatitis E infection.[56]

Viral hepatitis is liver inflammation from hepatitis A, B, C, D, and E. Acute hepatitis A, compared to hepatitis C and B, is associated with increased serum ALT and AST levels, reaching 3000 to 4000 IU/L. The diagnosis of chronic hepatitis will have elevations in ALT levels for greater than 6 months.[54] Common clinical signs of viral hepatitis include jaundice, anorexia, fatigue, vomiting, fever, nausea, and hepatomegaly. The risk factors for viral hepatitis include travel to areas where hepatitis is endemic, multiple sexual partners, occupational exposure to chemicals and hepatotoxicants, and intravenous drug use.[57] Hepatitis serology labs should also be ordered to confirm the diagnosis and the type of viral hepatitis.[58]

The most efficient aminotransferase threshold for diagnosing acute liver injury is 7 times the upper limit (sensitivity and specificity >95%).[59] In acute viral hepatitis, peak values of transaminase activity occur between the 7th and 12th days; activities then gradually decrease, reaching physiologic concentrations by the 3rd to 5th week if recovery is uneventful.[57] Peak activities bear no relationship to prognosis and may fall with the worsening of the patient’s condition, perhaps due to a lack of further functional hepatocytes to continue enzyme release.

The persistence of increased ALT for longer than 6 months after an episode of acute hepatitis is used to diagnose chronic hepatitis.[60] Most patients with chronic hepatitis have a maximum ALT of fewer than seven times the upper limit. ALT may be persistently normal in 15% to 50% of patients with chronic hepatitis C, but the likelihood of continuously normal ALT decreases with increasing measurements.[61] In patients with acute hepatitis C, ALT should be measured periodically over the next 1 to 2 years to determine if it stays normal.[62]

Ischemic liver injury, also known as ischemic hepatitis, occurs when there is an acute reduction in blood perfusion to the liver, leading to necrosis of hepatic centrilobular cells on histology.[63] Hepatic damage is higher in septic shock, where a decrease in blood perfusion to the liver is due to infection. A recent study revealed the incidence of abnormally elevated ALT was more sensitive to the diagnosis of ischemic hepatitis due to septic or hypovolemic shock.[64] In evaluating septic shock as a potential cause for ischemic liver injury, serum lactate, serum CRP, blood counts, D-dimer levels, and blood cultures should be measured. 

Medications can account for an elevation in ALT. Paracetamol toxicity (also known as acetaminophen) has been shown in a recent study to account for almost half of drug-induced liver injuries. In paracetamol toxicity, the levels of serum ALT are usually higher than 1,000 U/L.[56] Therefore, paracetamol toxicity should be among the differential diagnoses of patients with acute liver failure. A review of hepatotoxic medicines is vital in ensuring the proper diagnosis. Drugs associated with an elevation of transaminases include tacrine, imipramine, amitriptyline, isoniazid, pyrazinamide, rifampicin, ibuprofen, nimesulide, cotrimoxazole, phenytoin, dapsone.[45][43]

Non-alcoholic fatty liver disease (NAFLD) should merit consideration among the most common causes of abnormally elevated ALT levels in asymptomatic patients.[65] NAFLD is the fat accumulation within the liver in patients who do not consume alcohol. NAFLD has the potential to progress into hepatic fibrosis and cirrhosis, increasing liver-related morbidity and mortality.[66] NAFLD is usually associated with higher ALT and GGT levels in patients with impaired glucose tolerance or type 2 diabetes mellitus. NAFLD risk factors include morbid obesity, hyperglycemia, hypertriglyceridemia, hypertension, and decreased insulin sensitivity.[67] A NAFLD fibrosis score and radiological imaging such as CT or MRI of the liver should be considered to assess the severity and progression of NAFLD. The diagnosis of NAFLD is made with steatosis in 5% or greater of hepatocytes.[68]

In 1957, DeRitis described in a publication the ratio between AST and ALT in the diagnosis of viral hepatitis, where ALT is usually higher than AST.[69] Later, the usefulness of this ratio was highlighted in alcoholic hepatitis, where AST is mostly more elevated than ALT. Therefore, the ratio between AST and ALT is >2.0 for alcoholic hepatitis, 1.5 to <2.0 in acute viral hepatitis, and >1.0 in fibrosis and cirrhosis.[70] Many laboratories do not include this ratio in their reports because it is not specific, and hemolysis can affect AST.[71] The ratio is affected by the number of days post-exposure and the severity of the disease. Additional critical factors are the relatively short half-life of AST (18 hours) compared to ALT (47 hours), gender, and intra-individual variation of both AST and ALT.[72]

Quality Control and Lab Safety

The Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations require a laboratory to have quality control (QC) procedures to monitor the accuracy and precision of the complete testing process.[73] For non-waived tests, laboratory regulations require, at the minimum, analysis of at least 2 levels of control materials every 24 hours.[74] To ensure accurate results, laboratories can assay QC samples more frequently. The procedure is stable if the QC material result is within limits and patient samples are suitable. If not, the procedure is inaccurate, and patient samples may not be suitable. Corrective action is needed.[75]

The Levey-Jennings plot is the most common presentation for evaluating QC results. This representation displays sequential QC results over time, enabling a swift visual performance evaluation. Under stable conditions aligning with the procedure's specifications, the mean value signifies the anticipated QC result, while the standard deviation lines depict anticipated imprecision. Presuming a Gaussian (normal) distribution of imprecision, the results ideally demonstrate a uniform spread around the mean, with a higher frequency of observations closer to the mean compared to the extremes of the distribution.[76]

Quality control samples should be assayed after calibration or maintenance of an analyzer to verify the correct method performance.[77] To minimize QC when performing tests for which manufacturers’ recommendations are less than those required by the regulatory agency (such as once per month), the labs can develop an individualized quality control plan (IQCP) that involves performing a risk assessment of potential sources of error in all phases of testing and putting in place a QC plan to reduce the likelihood of errors.[78]

External quality control, also known as external quality assessment (EQA) or proficiency testing (PT), is a vital process for ensuring the accuracy and reliability of laboratory testing.[79] In this assessment, surrogate samples are provided by an independent external organization, and the laboratory is unaware of the expected values for these samples. The results obtained from analyzing these EQA/PT samples are compared with target values assigned to the samples. This comparison verifies that the laboratory's measurement procedures align with the expected performance standards. Participation in EQA/PT programs allows laboratories to evaluate and manage the quality of their testing routines with the support of an independent party. It provides valuable insights into individual laboratories' performance and helps standardize measurement procedures across different laboratories.[80] By enrolling in EQA/PT programs, laboratories can demonstrate their commitment to quality improvement and gain confidence in the accuracy of their testing processes.

Westgard rules represent a comprehensive set of statistical criteria employed in quality control practices within laboratories. These rules serve as analytical tools to detect errors or inconsistencies that might occur during the testing process.[81] Each Westgard rule targets specific deviations within quality control (QC) data, highlighting potential issues such as random errors, systematic shifts in means, trends in consecutive measurements, or extreme outliers.[82] In case of a rule violation, proper corrective and preventive action should be implemented before patient testing.[83] 

Biological variation data suggest that an imprecision of less than 9.7%, a bias of ±11.5%, and a total error of ±27.5% for ALT is required for clinical use of its determinations. In general, the imprecision target is easily met using current aminotransferase methods. However, it is important to note that while imprecision targets may be consistently met by current methods, ensuring compliance with bias and total error criteria is equally essential.[84] Focusing solely on meeting imprecision targets might overshadow the necessity of addressing bias and overall total error, which are critical factors influencing the accuracy and reliability of clinical interpretations.

Collecting blood samples is a crucial yet potentially hazardous task, bearing risks for clinicians and patients if not executed properly.[85] Structured educational programs are essential to mitigate these risks. These programs aim to standardize blood collection, educate individuals on associated risks, and address common mistakes, enhancing laboratory safety standards.[86]

Clinicians should demonstrate proficiency before engaging in patient care involving blood collection. This involves understanding and adhering to protocols that prioritize safety measures. Personal protective equipment (PPE), such as single-use nonsterile gloves, eye protection, and masks in scenarios where exposure to blood is possible, serves as a frontline defense against accidental contamination or infection.[87] Additionally, using trays or tube holders during sample collection requires careful consideration. Protocols should be in place to prevent cross-contamination, especially when these items are used for multiple patients.[88]

Proper disposal of needles minimizes the risk of needle-stick injuries, and utilizing designated sharps containers ensures safe containment of used needles, significantly reducing the potential for accidental injuries.[89] Overall, comprehensive education, strict adherence to safety protocols, and the utilization of appropriate protective gear and disposal methods are fundamental in minimizing risks associated with blood sample collection for both healthcare personnel and patients.

Enhancing Healthcare Team Outcomes

Multi-disciplinary and interprofessional rounds are when medical and other health providers collaborate to enhance patient outcomes. Clinicians may review the significance of the hepatic function test panel in correlation with each patient's medical history and physical examination to detect any drug-induced hepatic injury and build a differential diagnosis. Changes in the patient's patterns of ALT and AST over time or other liver function tests may necessitate a referral to gastroenterologists. Clinical pharmacists can also advise about potential contraindications or hepatotoxic medication interactions. The charge nurse of each floor can communicate updates on a patient's response to treatment, other laboratory orders, and current disposition. A multi-disciplinary approach can ensure a higher quality of care and enhance outcomes.[90]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Sakagishi Y. [Alanine aminotransferase (ALT)]. Nihon Rinsho. 1995 May;53(5):1146-50. [PubMed: 7602770]

2.

Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther. 2012 Sep;92(3):332-9. [PubMed: 22871997]

3.

Sherman KE. Alanine aminotransferase in clinical practice. A review. Arch Intern Med. 1991 Feb;151(2):260-5. [PubMed: 1992953]

4.

Dufour DR. Alanine aminotransferase: is it healthy to be "normal"? Hepatology. 2009 Dec;50(6):1699-701. [PubMed: 19937679]

5.

Yip TC, Wong VW, Wong GL. Alanine Aminotransferase Level: The Road to Normal in 2021. Hepatol Commun. 2021 Nov;5(11):1807-1809. [PMC free article: PMC8557309] [PubMed: 34719129]

6.

Liu Z, Que S, Xu J, Peng T. Alanine aminotransferase-old biomarker and new concept: a review. Int J Med Sci. 2014;11(9):925-35. [PMC free article: PMC4081315] [PubMed: 25013373]

7.

Kaplan MM. Alanine aminotransferase levels: what's normal? Ann Intern Med. 2002 Jul 02;137(1):49-51. [PubMed: 12093245]

8.

Woreta TA, Alqahtani SA. Evaluation of abnormal liver tests. Med Clin North Am. 2014 Jan;98(1):1-16. [PubMed: 24266911]

9.

Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019 Feb;65:37-55. [PubMed: 30213667]

10.

Calvaruso V, Craxì A. Implication of normal liver enzymes in liver disease. J Viral Hepat. 2009 Aug;16(8):529-36. [PubMed: 19656288]

11.

Oren R. Serum liver enzymes--should we count on them? Liver Int. 2014 Feb;34(2):171-3. [PubMed: 24164713]

12.

Kalra A, Yetiskul E, Wehrle CJ, Tuma F. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Physiology, Liver. [PubMed: 30571059]

13.

Knell AJ. Liver function and failure: the evolution of liver physiology. J R Coll Physicians Lond. 1980 Jul;14(3):205-8. [PMC free article: PMC5373221] [PubMed: 7009850]

14.

Oh RC, Hustead TR, Ali SM, Pantsari MW. Mildly Elevated Liver Transaminase Levels: Causes and Evaluation. Am Fam Physician. 2017 Dec 01;96(11):709-715. [PubMed: 29431403]

15.

Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol. 2006 Jan;101(1):76-82. [PubMed: 16405537]

16.

Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003 May;98(5):960-7. [PubMed: 12809815]

17.

Bussler S, Vogel M, Pietzner D, Harms K, Buzek T, Penke M, Händel N, Körner A, Baumann U, Kiess W, Flemming G. New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase): Effects of age, sex, body mass index, and pubertal stage. Hepatology. 2018 Oct;68(4):1319-1330. [PubMed: 28926121]

18.

Chen KW, Meng FC, Shih YL, Su FY, Lin YP, Lin F, Lin JW, Chang WK, Lee CJ, Li YH, Hsieh CB, Lin GM. Sex-Specific Association between Metabolic Abnormalities and Elevated Alanine Aminotransferase Levels in a Military Cohort: The CHIEF Study. Int J Environ Res Public Health. 2018 Mar 19;15(3) [PMC free article: PMC5877090] [PubMed: 29562671]

19.

Leibowitz A, Klin Y, Gruenbaum BF, Gruenbaum SE, Kuts R, Dubilet M, Ohayon S, Boyko M, Sheiner E, Shapira Y, Zlotnik A. Effects of strong physical exercise on blood glutamate and its metabolite 2-ketoglutarate levels in healthy volunteers. Acta Neurobiol Exp (Wars). 2012;72(4):385-96. [PubMed: 23377269]

20.

Ruhl CE, Everhart JE. Diurnal variation in serum alanine aminotransferase activity in the US population. J Clin Gastroenterol. 2013 Feb;47(2):165-73. [PMC free article: PMC3545081] [PubMed: 23164687]

21.

Mera JR, Dickson B, Feldman M. Influence of gender on the ratio of serum aspartate aminotransferase (AST) to alanine aminotransferase (ALT) in patients with and without hyperbilirubinemia. Dig Dis Sci. 2008 Mar;53(3):799-802. [PubMed: 17717745]

22.

Qu HQ, Li Q, Grove ML, Lu Y, Pan JJ, Rentfro AR, Bickel PE, Fallon MB, Hanis CL, Boerwinkle E, McCormick JB, Fisher-Hoch SP. Population-based risk factors for elevated alanine aminotransferase in a South Texas Mexican-American population. Arch Med Res. 2012 Aug;43(6):482-8. [PMC free article: PMC3590902] [PubMed: 22959976]

23.

Wang S, Song J, Yang Y, Zhang Y, Chawla NV, Ma J, Wang H. Interaction between obesity and the Hypoxia Inducible Factor 3 Alpha Subunit rs3826795 polymorphism in relation with plasma alanine aminotransferase. BMC Med Genet. 2017 Jul 28;18(1):80. [PMC free article: PMC5534125] [PubMed: 28754107]

24.

Bekkelund SI, Jorde R. Alanine Aminotransferase and Body Composition in Obese Men and Women. Dis Markers. 2019;2019:1695874. [PMC free article: PMC6732629] [PubMed: 31534560]

25.

Sohn W, Jun DW, Kwak MJ, Park Q, Lee KN, Lee HL, Lee OY, Yoon BC, Choi HS. Upper limit of normal serum alanine and aspartate aminotransferase levels in Korea. J Gastroenterol Hepatol. 2013 Mar;28(3):522-9. [PubMed: 22497339]

26.

Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980 Jul;55(7):434-8. [PubMed: 7382552]

27.

Akuyam SA, Abubakar A, Lawal N, Yusuf R, Aminu SM, Hassan A, Musa A, Bello AK, Yahaya IA, Okafor PA. Assessment of biochemical liver function tests in relation to age among steady state sickle cell anemia patients. Niger J Clin Pract. 2017 Nov;20(11):1428-1433. [PubMed: 29303127]

28.

Mukherjee T, Hanes J, Tews I, Ealick SE, Begley TP. Pyridoxal phosphate: biosynthesis and catabolism. Biochim Biophys Acta. 2011 Nov;1814(11):1585-96. [PubMed: 21767669]

29.

di Salvo ML, Contestabile R, Safo MK. Vitamin B(6) salvage enzymes: mechanism, structure and regulation. Biochim Biophys Acta. 2011 Nov;1814(11):1597-608. [PubMed: 21182989]

30.

Vanderlinde RE. Review of pyridoxal phosphate and the transaminases in liver disease. Ann Clin Lab Sci. 1986 Mar-Apr;16(2):79-93. [PubMed: 3008634]

31.

Tutor-Crespo MJ, Hermida J, Tutor JC. Activation of serum aminotransferases by pyridoxal-5' -phosphate in epileptic patients treated with anticonvulsant drugs. Clin Biochem. 2004 Aug;37(8):714-7. [PubMed: 15302618]

32.

Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005 Feb 01;172(3):367-79. [PMC free article: PMC545762] [PubMed: 15684121]

33.

Córdoba J, O'Riordan K, Dupuis J, Borensztajin J, Blei AT. Diurnal variation of serum alanine transaminase activity in chronic liver disease. Hepatology. 1998 Dec;28(6):1724-5. [PubMed: 9890798]

34.

Lukicheva TI, Men'shikov VV. [The preanalytical stage of under measuring of concentration of catalytic activity of enzymes: the characteristics and tasks of standardization]. Klin Lab Diagn. 2012 Jun;(6):9-12. [PubMed: 22946217]

35.

Magnette A, Chatelain M, Chatelain B, Ten Cate H, Mullier F. Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories. Thromb J. 2016;14:49. [PMC free article: PMC5154122] [PubMed: 27999475]

36.

Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med. 2006;44(6):750-9. [PubMed: 16729864]

37.

Lee NY. Types and Frequencies of Pre-Analytical Errors in the Clinical Laboratory at the University Hospital of Korea. Clin Lab. 2019 Sep 01;65(9) [PubMed: 31532088]

38.

Najat D. Prevalence of Pre-Analytical Errors in Clinical Chemistry Diagnostic Labs in Sulaimani City of Iraqi Kurdistan. PLoS One. 2017;12(1):e0170211. [PMC free article: PMC5249186] [PubMed: 28107395]

39.

Plebani M. The detection and prevention of errors in laboratory medicine. Ann Clin Biochem. 2010 Mar;47(Pt 2):101-10. [PubMed: 19952034]

40.

Lippi G, von Meyer A, Cadamuro J, Simundic AM. Blood sample quality. Diagnosis (Berl). 2019 Mar 26;6(1):25-31. [PubMed: 29794250]

41.

Maire I. [Determination of the activity of alanine aminotransferase]. Rev Fr Transfus Hemobiol. 1990 Mar;33(2):101-9. [PubMed: 2200419]

42.

Mäntele W, Deniz E. UV-VIS absorption spectroscopy: Lambert-Beer reloaded. Spectrochim Acta A Mol Biomol Spectrosc. 2017 Feb 15;173:965-968. [PubMed: 27727137]

43.

Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014 Jan;89(1):95-106. [PubMed: 24388027]

44.

Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R., Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005 Aug;129(2):512-21. [PubMed: 16083708]

45.

Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002 Aug;36(2):451-5. [PubMed: 12143055]

46.

Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, Engle RE, Nguyen H, Emerson SU, Purcell RH, Tillmann HL, Gu J, Serrano J, Hoofnagle JH., Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011 Nov;141(5):1665-72.e1-9. [PMC free article: PMC3654540] [PubMed: 21855518]

47.

Lewis JH. The adaptive response (drug tolerance) helps to prevent drug-induced liver injury. Gastroenterol Hepatol (N Y). 2012 May;8(5):333-6. [PMC free article: PMC3424431] [PubMed: 22933867]

48.

Devarbhavi H. An Update on Drug-induced Liver Injury. J Clin Exp Hepatol. 2012 Sep;2(3):247-59. [PMC free article: PMC3940315] [PubMed: 25755441]

49.

Telles-Correia D, Barbosa A, Cortez-Pinto H, Campos C, Rocha NB, Machado S. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther. 2017 Feb 06;8(1):26-38. [PMC free article: PMC5292604] [PubMed: 28217372]

50.

Purkins L, Love ER, Eve MD, Wooldridge CL, Cowan C, Smart TS, Johnson PJ, Rapeport WG. The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase I unit. Br J Clin Pharmacol. 2004 Feb;57(2):199-208. [PMC free article: PMC1884438] [PubMed: 14748819]

51.

Hall P, Cash J. What is the real function of the liver 'function' tests? Ulster Med J. 2012 Jan;81(1):30-6. [PMC free article: PMC3609680] [PubMed: 23536736]

52.

Agrawal S, Dhiman RK, Limdi JK. Evaluation of abnormal liver function tests. Postgrad Med J. 2016 Apr;92(1086):223-34. [PubMed: 26842972]

53.

Malakouti M, Kataria A, Ali SK, Schenker S. Elevated Liver Enzymes in Asymptomatic Patients - What Should I Do? J Clin Transl Hepatol. 2017 Dec 28;5(4):394-403. [PMC free article: PMC5719197] [PubMed: 29226106]

54.

Gowda S, Desai PB, Hull VV, Math AA, Vernekar SN, Kulkarni SS. A review on laboratory liver function tests. Pan Afr Med J. 2009 Nov 22;3:17. [PMC free article: PMC2984286] [PubMed: 21532726]

55.

Peralta C, Jiménez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu. J Hepatol. 2013 Nov;59(5):1094-106. [PubMed: 23811302]

56.

Galvin Z, McDonough A, Ryan J, Stewart S. Blood alanine aminotransferase levels >1,000 IU/l - causes and outcomes. Clin Med (Lond). 2015 Jun;15(3):244-7. [PMC free article: PMC4953107] [PubMed: 26031973]

57.

Abutaleb A, Kottilil S. Hepatitis A: Epidemiology, Natural History, Unusual Clinical Manifestations, and Prevention. Gastroenterol Clin North Am. 2020 Jun;49(2):191-199. [PMC free article: PMC7883407] [PubMed: 32389358]

58.

Seto DS. Viral hepatitis. Pediatr Clin North Am. 1979 May;26(2):305-14. [PubMed: 379776]

59.

Schwarz KB, Balistreri W. Viral hepatitis. J Pediatr Gastroenterol Nutr. 2002;35 Suppl 1:S29-32. [PubMed: 12151818]

60.

Ryder SD, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: Acute hepatitis. BMJ. 2001 Jan 20;322(7279):151-3. [PMC free article: PMC1119417] [PubMed: 11159575]

61.

Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019 Oct 19;394(10207):1451-1466. [PubMed: 31631857]

62.

Kaplan DE. Hepatitis C Virus. Ann Intern Med. 2020 Sep 01;173(5):ITC33-ITC48. [PubMed: 32866406]

63.

Guo G, Wu XZ, Su LJ, Yang CQ. Clinical features of ischemic hepatitis caused by shock with four different types: a retrospective study of 328 cases. Int J Clin Exp Med. 2015;8(9):16670-5. [PMC free article: PMC4659089] [PubMed: 26629201]

64.

Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med. 2000 Aug 01;109(2):109-13. [PubMed: 10967151]

65.

Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):597-601. [PMC free article: PMC4566337] [PubMed: 26425466]

66.

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018 Jul;24(7):908-922. [PMC free article: PMC6553468] [PubMed: 29967350]

67.

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015 Apr;62(1 Suppl):S47-64. [PubMed: 25920090]

68.

Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. Nutr Clin Pract. 2020 Feb;35(1):72-84. [PubMed: 31840865]

69.

De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis: the transaminase serum activities. 1957. Clin Chim Acta. 2006 Jul 23;369(2):148-52. [PubMed: 16781697]

70.

Majhi S, Baral N, Lamsal M, Mehta KD. De Ritis ratio as diagnostic marker of alcoholic liver disease. Nepal Med Coll J. 2006 Mar;8(1):40-2. [PubMed: 16827089]

71.

Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988 Sep;95(3):734-9. [PubMed: 3135226]

72.

Botros M, Sikaris KA. The de ritis ratio: the test of time. Clin Biochem Rev. 2013 Nov;34(3):117-30. [PMC free article: PMC3866949] [PubMed: 24353357]

73.

Ehrmeyer SS, Laessig RH. Has compliance with CLIA requirements really improved quality in US clinical laboratories? Clin Chim Acta. 2004 Aug 02;346(1):37-43. [PubMed: 15234634]

74.

Lala V, Zubair M, Minter DA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Liver Function Tests. [PubMed: 29494096]

75.

Abdel GMT, El-Masry MI. Verification of quantitative analytical methods in medical laboratories. J Med Biochem. 2021 Jun 05;40(3):225-236. [PMC free article: PMC8199534] [PubMed: 34177366]

76.

Liao CM, Lin CM, Kuo CC, Chen MS, Huang CY, Lin CY. Adjusting Quality Control Chart Limits for WBC, RBC, Hb, and PLT Counts to Reduce Daily Control Risks in Hospital Laboratory. Risk Manag Healthc Policy. 2020;13:3039-3049. [PMC free article: PMC7751786] [PubMed: 33364865]

77.

Kearney E. Internal quality control. Methods Mol Biol. 2013;1065:277-89. [PubMed: 23996371]

78.

Bruno LC. IQCP: Guideline and Helpful Tools for Implementation. Lab Med. 2016 Nov;47(4):e42-e46. [PubMed: 27708173]

79.

Miller WG, Jones GR, Horowitz GL, Weykamp C. Proficiency testing/external quality assessment: current challenges and future directions. Clin Chem. 2011 Dec;57(12):1670-80. [PubMed: 21965556]

80.

Kristensen GB, Meijer P. Interpretation of EQA results and EQA-based trouble shooting. Biochem Med (Zagreb). 2017 Feb 15;27(1):49-62. [PMC free article: PMC5382861] [PubMed: 28392726]

81.

Bayat H. Selecting multi-rule quality control procedures based on patient risk. Clin Chem Lab Med. 2017 Oct 26;55(11):1702-1708. [PubMed: 28236626]

82.

Carroll TA, Pinnick HA, Carroll WE. Probability and the Westgard Rules. Ann Clin Lab Sci. 2003 Winter;33(1):113-4. [PubMed: 12661907]

83.

Poh DKH, Lim CY, Tan RZ, Markus C, Loh TP. Internal quality control: Moving average algorithms outperform Westgard rules. Clin Biochem. 2021 Dec;98:63-69. [PubMed: 34534518]

84.

Carobene A, Braga F, Roraas T, Sandberg S, Bartlett WA. A systematic review of data on biological variation for alanine aminotransferase, aspartate aminotransferase and γ-glutamyl transferase. Clin Chem Lab Med. 2013 Oct;51(10):1997-2007. [PubMed: 24072574]

85.

Giavarina D, Lippi G. Blood venous sample collection: Recommendations overview and a checklist to improve quality. Clin Biochem. 2017 Jul;50(10-11):568-573. [PubMed: 28242283]

86.

Lillo R, Salinas M, Lopez-Garrigos M, Naranjo-Santana Y, Gutiérrez M, Marín MD, Miralles M, Uris J. Reducing preanalytical laboratory sample errors through educational and technological interventions. Clin Lab. 2012;58(9-10):911-7. [PubMed: 23163106]

87.

Stankovic AK, Blond BJ, Coulter SN, Long T, Lindholm PF. Preanalytic Competency Assessment: A Q-Probes Study Involving 46 Health Care Institutions, 447 Blood Collectors/Phlebotomists, and 2212 Individual Assessments. Arch Pathol Lab Med. 2023 Mar 01;147(3):304-312. [PubMed: 35802937]

88.

Scales K. A practical guide to venepuncture and blood sampling. 2008 Mar 26-Apr 1Nurs Stand. 22(29):29-36. [PubMed: 18450285]

89.

De Carli G, Abiteboul D, Puro V. The importance of implementing safe sharps practices in the laboratory setting in Europe. Biochem Med (Zagreb). 2014;24(1):45-56. [PMC free article: PMC3936965] [PubMed: 24627714]

90.

Gurses AP, Xiao Y. A systematic review of the literature on multidisciplinary rounds to design information technology. J Am Med Inform Assoc. 2006 May-Jun;13(3):267-76. [PMC free article: PMC1513658] [PubMed: 16501176]

Disclosure: Kevin Moriles declares no relevant financial relationships with ineligible companies.

Disclosure: Muhammad Zubair declares no relevant financial relationships with ineligible companies.

Disclosure: Samy Azer declares no relevant financial relationships with ineligible companies.